GlaxoSmithKline Pharmaceuticals Ltd (GLAXO):企業の財務・戦略的SWOT分析

◆英語タイトル:GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C2508
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:74
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline Pharmaceuticals Ltd (GSK India), a subsidiary of GlaxoSmithKline Plc manufactures and markets prescription medicines and vaccines. The prescription medicines includes therapeutic areas such as, analgesic, anti-infective, anti-inflammatory, anti-parasitic, cardiovascular, dermatology, diabetes, endocrine, gastrointestinal, gynaecology, immunosupressants, nutritional, respiratory, central nervous system (CNS) and oncology. The company offers a range of vaccines for the prevention of hepatitis A, hepatitis B, influenzae, diphtheria, tetanus, pertussis, rotavirus, tetanus toxoid, reduced diphtheria toxoid, human papillomavirus vaccine and others. GSK India is headquartered in Mumbai, Maharashtra, India.

GlaxoSmithKline Pharmaceuticals Ltd Key Recent Developments

May 24,2018: GlaxoSmithKline Pharmaceuticals delivers strong Q4 performance with Revenue of 749 Cr and PBT before exceptionals growing 14%
Mar 16,2018: GlaxoSmithKline Pharmaceuticals: Change in Directorate
Feb 26,2018: Champion Baseball Pitcher Justin Verlander Teams Up with FLONASE Allergy Relief for a Homerun Allergy Season
Feb 07,2018: GlaxoSmithKline: Full year and fourth quarter 2017
Feb 02,2018: GlaxoSmithKline Pharmaceuticals delivers strong Q3 performance with Revenue of 704 Cr.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
GlaxoSmithKline Pharmaceuticals Ltd – Key Facts 6
GlaxoSmithKline Pharmaceuticals Ltd – Key Employees 7
GlaxoSmithKline Pharmaceuticals Ltd – Key Employee Biographies 8
GlaxoSmithKline Pharmaceuticals Ltd – Key Operational Employees 9
GlaxoSmithKline Pharmaceuticals Ltd – Major Products and Services 10
GlaxoSmithKline Pharmaceuticals Ltd – History 16
GlaxoSmithKline Pharmaceuticals Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Joint Venture 18
Section 2 – Company Analysis 19
Company Overview 19
GlaxoSmithKline Pharmaceuticals Ltd – Business Description 20
GlaxoSmithKline Pharmaceuticals Ltd – Corporate Strategy 21
GlaxoSmithKline Pharmaceuticals Ltd – SWOT Analysis 22
SWOT Analysis – Overview 22
GlaxoSmithKline Pharmaceuticals Ltd – Strengths 22
GlaxoSmithKline Pharmaceuticals Ltd – Weaknesses 23
GlaxoSmithKline Pharmaceuticals Ltd – Opportunities 24
GlaxoSmithKline Pharmaceuticals Ltd – Threats 25
GlaxoSmithKline Pharmaceuticals Ltd – Key Competitors 26
Section 3 – Company Financial Ratios 27
Financial Ratios – Capital Market Ratios 27
Financial Ratios – Annual Ratios 28
Performance Chart 31
Financial Performance 31
Financial Ratios – Ratio Charts 32
Section 4 – Company’s Lifesciences Financial Deals and Alliances 33
GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33
GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34
GlaxoSmithKline Pharmaceuticals Ltd, Recent Deals Summary 35
Section 5 – Company’s Recent Developments 36
May 24, 2018: GlaxoSmithKline Pharmaceuticals delivers strong Q4 performance with Revenue of 749 Cr and PBT before exceptionals growing 14% 36
Mar 16, 2018: GlaxoSmithKline Pharmaceuticals: Change in Directorate 37
Feb 07, 2018: GlaxoSmithKline: Full year and fourth quarter 2017 38
Feb 02, 2018: GlaxoSmithKline Pharmaceuticals delivers strong Q3 performance with Revenue of 704 Cr. 64
Oct 25, 2017: GlaxoSmithKline Pharmaceuticals India records a Revenue increase of 5% 65
Oct 25, 2017: GlaxoSmithKline Pharmaceuticals Appointment of Ms. Puja Thakur as Whole-time Director and Chief Financial officer 66
Jul 25, 2017: GlaxoSmithKline Pharmaceuticals QI performance temporarily impacted by GST trade channel destocking whilst fundamentals remain intact 67
May 19, 2017: GlaxoSmithKline Pharmaceuticals records 11% Sales growth for Q4, FY 2016-17 68
Feb 11, 2017: GlaxoSmithKline Pharmaceuticals announces executive director change 69
Section 6 – Appendix 70
Methodology 70
Ratio Definitions 70
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
GlaxoSmithKline Pharmaceuticals Ltd, Key Facts 6
GlaxoSmithKline Pharmaceuticals Ltd, Key Employees 7
GlaxoSmithKline Pharmaceuticals Ltd, Key Employee Biographies 8
GlaxoSmithKline Pharmaceuticals Ltd, Key Operational Employees 9
GlaxoSmithKline Pharmaceuticals Ltd, Major Products and Services 10
GlaxoSmithKline Pharmaceuticals Ltd, History 16
GlaxoSmithKline Pharmaceuticals Ltd, Joint Venture 18
GlaxoSmithKline Pharmaceuticals Ltd, Key Competitors 26
GlaxoSmithKline Pharmaceuticals Ltd, Ratios based on current share price 27
GlaxoSmithKline Pharmaceuticals Ltd, Annual Ratios 28
GlaxoSmithKline Pharmaceuticals Ltd, Annual Ratios (Cont...1) 29
GlaxoSmithKline Pharmaceuticals Ltd, Annual Ratios (Cont...2) 30
GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33
GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34
GlaxoSmithKline Pharmaceuticals Ltd, Recent Deals Summary 35
Currency Codes 70
Capital Market Ratios 70
Equity Ratios 71
Profitability Ratios 71
Cost Ratios 72
Liquidity Ratios 72
Leverage Ratios 73
Efficiency Ratios 73

List of Figures
GlaxoSmithKline Pharmaceuticals Ltd, Performance Chart (2015 - 2018) 31
GlaxoSmithKline Pharmaceuticals Ltd, Ratio Charts 32
GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33
GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 34

★海外企業調査レポート[GlaxoSmithKline Pharmaceuticals Ltd (GLAXO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kala Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company which focuses on nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s lead program MPP nanosuspension of an ophthalmic corticosteroid is under phase …
  • Quadra – Power Generation (TGKD):企業の財務・戦略的SWOT分析
    Quadra - Power Generation (TGKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Avanza Bank Holding AB:企業の戦略・SWOT・財務分析
    Avanza Bank Holding AB - Strategy, SWOT and Corporate Finance Report Summary Avanza Bank Holding AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Pictet & Cie Group SCA:企業の戦略・SWOT・財務情報
    Pictet & Cie Group SCA - Strategy, SWOT and Corporate Finance Report Summary Pictet & Cie Group SCA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Alnylam Pharmaceuticals Inc (ALNY)-製薬・医療分野:企業M&A・提携分析
    Summary Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiova …
  • Silverlake Axis Ltd:企業の戦略・SWOT・財務分析
    Silverlake Axis Ltd - Strategy, SWOT and Corporate Finance Report Summary Silverlake Axis Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Patel Engineering Ltd:企業の戦略・SWOT・財務分析
    Patel Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Patel Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Entertainment One Ltd.:企業の戦略・SWOT・財務分析
    Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report Summary Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Edisun Power Europe AG (ESUN):企業の財務・戦略的SWOT分析
    Summary Edisun Power Europe AG (Edisun Power) is a solar power producer. The company finances, develops and operates solar power plants in various European countries. It offers technical studies, legal and financial studies, custom design, installation, work monitoring, and operation and maintenance …
  • Northern Minerals Ltd (GPP):企業の財務・戦略的SWOT分析
    Summary Northern Minerals Ltd (Northern Minerals) formerly known as Greenpower Energy Limited, is a mining, exploration and development company. The company’s business activities include acquisition, exploration, and development of petroleum, mineral and hydrothermal exploration properties. It explo …
  • Schnell Biopharmaceuticals Inc (003060)-製薬・医療分野:企業M&A・提携分析
    Summary Schnell Biopharmaceuticals Inc (Schnell), formerly Korea Schnell Pharma Co., Ltd. is a healthcare company that offers agents and antibiotics. The company provides pharmaceutical products including amino acid infusion agents and antibiotics. Its products portfolio includes antibiotics, infusi …
  • Bonheur ASA (BON):企業の財務・戦略的SWOT分析
    Summary Bonheur ASA (Bonheur) is an oil and gas investment service provider that offers investment services for various energy sectors. The company invests in renewable energy, cruise, shipping and offshore wind, offshore drilling, and other investments. It operates shipping vessels for transport an …
  • University of Glasgow-製薬・医療分野:企業M&A・提携分析
    Summary University of Glasgow (UOG) is an educational and research institute that offers undergraduate, post graduate, and online programs. The institute operates through its departments for law, medicine, veterinary medicine and dentistry. It offers courses across various disciplines that include a …
  • Voith Hydro Holding GmbH & Co KG:企業の戦略的SWOT分析
    Voith Hydro Holding GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Excision BioTherapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Excision BioTherapeutics Inc (Excision BioTherapeutics) is a developer of gene editing therapeutics for the treatment of infectious diseases. The company’s products comprise EBT101, a HIV CRISPR Cas9 gRNA multiplex biologic for the prevention of Human Immunodeficiency Virus; EBT103, a PML JC …
  • Spectral Medical Inc (EDT):医療機器:M&Aディール及び事業提携情報
    Summary Spectral Medical Inc (Spectral), formerly Spectral Diagnostics Inc, is a biotechnology company that develops and commercializes diagnostic solutions for patient management. The company’s products comprise EAA, toraymyxin and reagents, among others. Its EAA is an endotoxin activity assay, whi …
  • Reitmans (Canada) Limited (RET.A):企業の財務・戦略的SWOT分析
    Reitmans (Canada) Limited (RET.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Helix Energy Solutions Group Inc (HLX):企業の財務・戦略的SWOT分析
    Summary Helix Energy Solutions Group Inc (Helix Energy) is an oil and gas company that provides offshore energy services. The company provides well intervention, subsea engineering and contracting services. Its well intervention services comprise riserless intervention and riser based operations, st …
  • Nippon Paper Industries Co., Ltd.:企業の戦略・SWOT・財務情報
    Nippon Paper Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Paper Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • InMed Pharmaceuticals Inc (IN)-製薬・医療分野:企業M&A・提携分析
    Summary InMed Pharmaceuticals Inc (InMed), formerly Cannabis Technologies Inc, is a pre-clinical stage biopharmaceutical company which develops, produces and markets plant cannabinoid based pharmaceutical products to related healthcare markets. The company's pipeline products include INM-750 and INM …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆